as the PhD student and supervised by C.M.A., with the main goal of exploring several novel histopathological markers, including tumor microenvironment factors, and molecular biomarkers, such as CDX2 immunohistochemical expression, and how they relate to established clinical, histopathological, and molecular parameters, as well as patient outcomes, in order to understand their impact on CRC prognosis. The gene discussed is CDX2; the disease is neoplasm.